Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-week Randomized, Placebo-Controlled, Phase IIb Study.

about

Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.

P2860

Q47552016-375E4689-5477-4537-90C8-77E92D5B45DF Q55052878-47EECFC6-3B9F-41A4-BAF1-144F647E89C5

P2860

Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-week Randomized, Placebo-Controlled, Phase IIb Study.

Item

http://www.wikidata.org/entity/Q46083219

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Efficacy and Safety of Atacice ...... o-Controlled, Phase IIb Study.

@en

Efficacy and Safety of Atacice ...... o-Controlled, Phase IIb Study.

@nl

type

Item

label

Efficacy and Safety of Atacice ...... o-Controlled, Phase IIb Study.

@en

Efficacy and Safety of Atacice ...... o-Controlled, Phase IIb Study.

@nl

prefLabel

Efficacy and Safety of Atacice ...... o-Controlled, Phase IIb Study.

@en

Efficacy and Safety of Atacice ...... o-Controlled, Phase IIb Study.

@nl

P1476

Efficacy and Safety of Atacice ...... o-Controlled, Phase IIb Study.

@en

P2093

Amy Kao

http://www.w3.org/2001/XMLSchema#string

Daniel J Wallace

http://www.w3.org/2001/XMLSchema#string

Joan T Merrill

http://www.w3.org/2001/XMLSchema#string

Patricia A Fraser

http://www.w3.org/2001/XMLSchema#string

Peter Chang

http://www.w3.org/2001/XMLSchema#string

Stephen Wax

http://www.w3.org/2001/XMLSchema#string

P2860

Unmet medical needs in systemic lupus erythematosus

APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

The 1982 revised criteria for the classification of systemic lupus erythematosus

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

P31

scholarly article

P356

10.1002/ART.40360

http://www.w3.org/2001/XMLSchema#string

P50

David A. Isenberg

P577

2017-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29073347

http://www.w3.org/2001/XMLSchema#string

P921

placebo

P932

6099253

http://www.w3.org/2001/XMLSchema#string

Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-week Randomized, Placebo-Controlled, Phase IIb Study.

about

P2860

P2860

Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-week Randomized, Placebo-Controlled, Phase IIb Study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P50

P577

P698

P921

P932